Barclays raised the firm’s price target on Crispr Therapeutics (CRSP) to $61 from $56 and keeps an Equal Weight rating on the shares following the approval of Casgevy. Both label and pricing appear favorable for commercial uptake for Casgevy given the black-box warning and stringent monitoring requirements for Bluebird’s (BLUE) Lyfgenia, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CRSP:
- Vertex (NASDAQ:VRTX), CRISPR Therapeutics Slip despite Sickle Cell Treatment Approval
- Crispr says Casgevy approval triggers $200M milestone payment
- Vertex sets $2.2M as U.S. wholesale acquisition cost for Casgevy
- Vertex and Crispr announce FDA approval of Casgevy for sickle cell disease
- Mizuho sees black box warning just for Bluebird, not Crispr
